The data set for Saudi Arabia included 6097 readers, 35,747 sensors, and 40 million automatic glucose measurements. Higher scanning frequency in flash glucose users from Saudi Arabia is associated with lower eA1c, higher TIR, lower glucose variability and less time in hypoglycemia or hyperglycemia. 

The data set included 12,370 readers, with data from 131,639 separate glucose sensors. In Israel, people with diabetes under real-world conditions recorded higher rates of FreeStyle Libre scanning. These higher scan rates were associated with improvements in time in range, estimated HbA1c, and reduced time with glucose levels of >180 mg/dL or <54 mg/dL.

Data comprising 16,331 readers (163,762 sensors) were analyzed. Increasing scan rates were associated with more time in range, less time in hyperglycemia, and a lower standard deviation of glucose. These outcomes among Dutch FLASH users suggest that with higher scan rate glycemic control improves.

This analysis used 5,804 readers from Argentina and 950,234 readers worldwide. A strong association was observed between highest scanning frequency and better glucose metrics, including less time below 54 mg/dL, less time above 250 mg/dL, lower estimated HbA1c level, lower glucose coefficient of variability (CV) and longer time within the therapeutic target (70 to 180 mg/dL). 

Data from the Polish population were collected from 10,679 readers and 92,627 sensors. The worldwide database included information from 981,876 readers and 11,179,229 sensors. On average, the users of isCGMS from Poland achieved lower estimated HbA1c, spent more time in range, and less time-above-range. The analyzed glucometrics improved as the scan rate frequency increased. The data also show that in real-life practice, a large number of patients may be willing to perform scanning more frequently than is usually assumed.

App users experienced lower glucose variability, lower average glucose, less time in hyperglycemia, and greater time in range than reader users. The observed differences may be driven by the data sharing features inherent in the app. By sharing glucose data with one’s clinical team, healthcare professionals and patients may be able to make more informed treatment decisions. 

The data comprised 688,640 readers and 7,329,052 sensors worldwide and included 17,691 readers and 147,166 sensors from Brazil. Similar to previous analyses, increased scan frequency was associated with better glycemic control – in this case, lower estimated HbA1c, lower time in hyperglycemia, and more time in range. 

Spanish users (n=22,949) collected 37.1 million glucose scans and checked glucose values via a mean of 13 scans/day. High scan rates were associated with the favorable glycemic markers of increased time-in-range and reduced time in hyperglycemia and hypoglycemia, and glucose variability

Data from 97,788 French patients from Sept 2014 - Sept 2018 were analyzed. When scan frequency was increased, estimated HbA1c was reduced, time in range was increased, and time in hypoglycemia was reduced. This study confirms that the frequency of FreeStyle Libre scans is associated with improved metabolic control, including time in range and time spent in hypoglycemia. 

De-identified glucose results from 6,802 users with at least six months of data were analyzed after dividing into high, medium and low-risk groups based on time spent in hypoglycemia or hyperglycemia. The analysis determined that under real-world conditions, flash monitoring was associated with rapid and sustained reduction in dysglycemia with high-frequency scanners demonstrating more significant reduction in hyperglycemia. 

Over 50,000 readers were included and over 90% of the data was from the seven initial FreeStyle Libre launch countries. Users performed an average of 16.3 glucose scans per day, almost four times more than average daily blood glucose checks previously reported. Higher scanning frequency was associated with better glycaemic measures including lower estimated HbA1c, decreased time in hyper and hypoglycemia and increased time in euglycemia with reduction in hypoglycemic exposure.